

Fig. 1. Nucleotide sequence of the human *MDR1* gene promoter. Positions of nucleotide variants are in bold and are underlined. The exons are boxed. The location of variants in the coding region is relative to the initiation site for translation, which is defined as +1 based on the cDNA nucleotide sequence. The position in the promoter region is relative to the nucleotide sequence immediately preceding exon 1, which is defined as -1a.

region altered binding for transcription factors, we performed EMSA using nuclear extracts prepared from HepG2 cells. By competition assays using an excess of unlabeled probe, allele-specific binding of nuclear proteins was observed when the nuclear extracts were incubated with probes, including -1517a C (complex I) and -1459a G (complex II) (Fig. 4, A and B). Also, strong nuclear protein-DNA binding (complex III) was observed with the probe containing the -1017a T allele when compared with the -1017a C allele (Fig. 4C). The higher binding completely disappeared under an excess of unlabeled -1017a T probe, and weaker inhibition of the binding was observed with the -1017a C probe. With the -145/-129 C/T and G/T probes, nuclear protein-DNA binding (complex VI) was detected, but with the C/C probe it was not detected or was much weaker (Fig. 4D). The protein-DNA binding was completely inhibited by an excess of unlabeled C/T and G/T probes, and slightly competed with by an excess of unlabeled C/C probe. No nuclear protein-DNA

binding was observed when the probes containing the -41a A/G and -145 G/C alleles were incubated with nuclear extracts.

Correlation between Placental *MDR1* mRNA Expression and Methylation Status at CpG Sites in the *MDR1* Promoter Region. The proximal region of the human *MDR1* is rich in CpG (Fig. 5A). This region including the Y box and GC box elements is required for activation of the *MDR1* promoter. We focused on the CpG-rich proximal region in the *MDR1* gene and determined the relationship between methylation status at each CpG site and *MDR1* mRNA expression using placenta with promoter haplotype 1/1 and 3435 C/C genotypes. Results of a bisulfite sequencing analysis of 26 CpG sites in seven subjects, whose *MDR1* levels varied considerably, are shown in Fig. 5B. In all samples, methylated CpG sites were found upstream of the promoter region. Moreover, an interindividual difference in methylation status was observed; however, no clear associa-

TABLE 1
Variants in promoter region of the *MDR1* gene in Japanese ($n = 94$) and Caucasian ($n = 96$) subjects

Location	Position	Allele	Nucleotide Sequence	Allele Frequency		Genotype	Frequency	
				Japanese	Caucasian		Japanese	Caucasian
Promoter	-1517a ^a	T ^b	agggTttaa	0.920 (0.881-0.959) ^c	1.000	T/T T/C C/C	0.840 0.160 0.000	1.000 0.000 0.000
		C	agggCttaa	0.080 (0.041-0.119)	0.000			
		G ^b	gtgaGataa	0.750 (0.688-0.812)	1.000	G/G G/A	0.553 0.394	1.000 0.000
	-1459a ^a	A	gtgaAataa	0.250 (0.188-0.312)	0.000	A/A	0.053	0.000
		GA ^b	cagaGAtcat	1.000 (0.985-1.005)	0.995	GA/GA GA/- -/-	1.000 0.000 0.000	0.990 0.010 0.000
	-1423a ^a	Deletion	caga_tcat	0.000	0.005 (-0.027-0.015)			
		CCATC ^b	aagaCCATCctgg	0.963 (0.936-0.990)	1.000	CCATC/CCATC CCATC/- -/-	0.926 0.074 0.000	1.000 0.000 0.000
	-1132a ^a	Deletion	aaga_ctgg	0.037 (0.01-0.064)	0.000			
		T ^b	atggTgtga	0.920 (0.881-0.959)	0.984 (0.966-1.002)	T/T T/C C/C	0.840 0.160 0.000	0.969 0.031 0.000
	-1017a ^a	C	atggCgtga	0.08 (0.041-0.119)	0.016 (-0.002-0.034)			
		T ^b	attaTggct	0.995	1.000 (0.985-1.005)	T/T T/C C/C	0.989 0.011 0.000	1.000 0.000 0.000
	-824a ^a	C	attaCggct	0.005 (-0.027-0.015)	0.000			
		A ^b	agtgAtttt	1.000 (0.985-1.005)	0.995	A/A A/G G/G	1.000 0.000 0.000	0.990 0.010 0.000
	-755a ^a	G	agtgGtttt	0.000	0.005 (-0.027-0.015)			
		A ^b	cccaAtgat	0.894 (0.850-0.938)	1.000	A/A A/G G/G	0.798 0.191 0.011	1.000 0.000 0.000
	-41a ^a	G	cccaGtgat	0.106 (0.062-0.150)	0.000			
		C ^b	gaagCctga	0.968 (0.943-0.993)	1.000	C/C C/G G/G	0.936 0.064 0.000	1.000 0.000 0.000
	-145 ²	G	gaagGctga	0.032 (0.007-0.057)	0.000			
		T ^b	cgagTagcg	0.920 (0.881-0.959)	0.984 (0.966-1.002)	T/T T/C C/C	0.840 0.160 0.000	0.969 0.031 0.000
	Exon 1	-129 ²	C	cgagCagcg	0.080 (0.041-0.119)	0.016 (-0.002-0.034)		

^a Position is relative to the initiation site of exon 1a, which is defined as +1a.

^b Reference sequence GenBank accession no. AC002457.

^c The 95% confidence intervals are given in parentheses.

^d Position is relative to the initiation site of translation, which is defined as +1.

tion was observed. In addition, methylation was not observed around either the Y box or GC box element in most samples.

Discussion

Despite evidence supporting an association of coding SNPs with pharmacokinetics and pharmacodynamics, little is known about the presence or functional relevance of allelic variants in the promoter region of *MDR1*. We described 10 polymorphic variants in the *MDR1* promoter in Japanese and Caucasian populations. A-41aG, C-145G, and T-129C have been detected in the proximal promoter region of the *MDR1* gene as low frequency variants (Horinouchi et al., 2002; Tang et al., 2002; Kroetz et al., 2003). Here, we identified another seven variants. Their presence and frequency varied according to race. For example, C-145G was identified in Asian-Americans but not Caucasians (Kroetz et al., 2003). In the present study, this variant was observed only in Japanese. In addition, the new G-1459aA variant was the most frequent variant in Japanese (25.0%), but was not found in Caucasians.

The promoter region of the *MDR1* gene has been isolated

and sequenced (Ueda et al., 1987; Madden et al., 1993). The promoter has an initiator sequence at the transcriptional start site, without a TATA box (van Groenigen et al., 1993). Numerous studies have shown that the Y box (inverted CCAAT box) and GC box, recognized by the transcription factors NF-Y and Sp1, respectively, are required for efficient transcriptional regulation of the *MDR1* promoter (Goldsmith et al., 1993; Sundseth et al., 1997). Several studies suggest that a region upstream of the Y box negatively regulates the *MDR1* promoter activity (Ogura et al., 1992; Cornwell and Smith, 1993), although the exact positions of the negative element differ. However, our variants are not located within those *cis*-elements.

We identified 10 different *MDR1* promoter haplotypes using subcloning and direct sequencing methods. A comparison of *MDR1* haplotype pairs with placental and hepatic expression showed that haplotypes 1/2 and 1/3 were associated with increased mRNA expression, independent of the C3435T mutation in the coding region. Interestingly, haplotypes 2 and 3, in which T-1517a C, T-1017aC, and T-129C mutations occurred simultaneously in both populations, were associated

TABLE 2
Localization of variants and identification of the *MDR1* promoter haplotypes in Japanese and Caucasian subjects

Haplotype	Frequency										
	Japanese n = 94					Caucasians n = 96					
1	T	C	A	A	T	C	A	A	T	C	0.665 (0.598-0.732)*
2	C	C	G	A	C	C	G	A	C	C	0.043 (0.014-0.072)
3	C	C	G	A	C	C	G	A	C	C	0.037 (0.010-0.064)
4	T	T	A	A	T	T	A	A	T	T	0.191 (0.135-0.247)
5	T	T	A	A	T	T	A	A	T	T	0.027 (0.004-0.050)
6	T	T	A	A	T	T	A	A	T	T	0.032 (0.007-0.057)
7	T	T	A	A	T	T	A	A	T	T	0.005 (-0.005-0.015)
8	T	T	A	A	T	T	A	A	T	T	0.000
9	T	T	A	A	T	T	A	A	T	T	0.000
10	T	T	A	A	T	T	A	A	T	T	0.016
											0.010

* The 95% confidence intervals are given in parentheses.

TABLE 3
Haplotype configurations in promoter region of the *MDR1* gene in Japanese and Caucasian subjects

Promoter Haplotype Pair	Frequency	
	Japanese (n = 94)	Caucasian (n = 96)
1/1	0.447 (0.376-0.518)*	0.923 (0.885-0.961)
1/2	0.043 (0.014-0.072)	0.000
1/3	0.053 (0.021-0.085)	0.000
1/4	0.234 (0.173-0.295)	0.000
1/5	0.043 (0.014-0.072)	0.000
1/6	0.064 (0.029-0.099)	0.000
1/8	0.000	0.038 (0.011-0.065)
1/9	0.000	0.038 (0.011-0.065)
2/4	0.021 (0.001-0.0041)	0.000
2/5	0.011 (-0.004-0.026)	0.000
2/7	0.011 (-0.004-0.026)	0.000
3/4	0.021 (0.001-0.0041)	0.000
4/4	0.053 (0.021-0.085)	0.000

* The 95% confidence intervals are given in parentheses.




Fig. 2. Influence of *MDR1* promoter haplotypes and SNPs in the coding region on placental and hepatic *MDR1* mRNA levels in Japanese. Statistical significance between the two genotypes was analyzed with the Mann-Whitney *U* test.

with an increase in transcriptional activity in human hepatoma cell line. Moreover, we showed that the T-1517aC, T-1017aC, and T-129C variants affected putative transcriptional protein-DNA binding. Heterozygosity for the -129C allele is associated with a high level of transport activity of P-glycoprotein in hematopoietic stem cells (Calado et al., 2002). The tacrolimus oral dose requirement is higher in renal transplant recipients with the T/C allele than T/T allele at position -129 (Anglicheau et al., 2003). Although these findings are not significant because the T-129C variant was




Fig. 3. *MDR1* promoter region reporter gene constructs and their relative luciferase activity levels. The value for the haplotype 1 construct was set at 100%. Each value is the mean \pm S.D. of relative luciferase activity from four to five experiments.

rare, the C allele at position -129 may be associated with high level of expression of P-glycoprotein, resulting in an increase in transport activity and then a decrease in tacrolimus bioavailability after oral administration. In contrast to these haplotypes, haplotype 6 (G-1459A and C-145G variant) was associated with a low level of transcriptional activity in hepatoma cells. We found that the G-1459A variant inhibits the binding of unknown transcriptional factor to DNA. Therefore, allelic variants not only in the coding region but also in the promoter region of the *MDR1* gene, may be

important to the interindividual difference in P-glycoprotein expression.

We determined the interindividual difference in methylation status in the proximal promoter region of the *MDR1* gene using seven placentas whose mRNA levels varied considerably. Extensive methylation of the *MDR1* gene assembled into chromatin enriched with methylated CpG binding protein interfered with the binding of transcription factors to their elements, resulting in transcriptional repression of the gene (Jin and Scotto, 1998; El-Osta et al., 2002). In this study, the region upstream of the promoter region was relatively well methylated, but individual differences in methylation status were unlikely to cause large variation in *MDR1* mRNA expression. Nakayama et al. (1998) reported that methylation at CpG sites near the Y box was important for *MDR1* gene expression and was associated closely with clinical outcome in acute myeloid leukemia. However, we did not find any methylation around either the Y box or GC box element. Similar results for methylation status in the promoter region have been reported in CD8-positive cells (Fryxell et al., 1999). The element Sp1 protects the promoter from de novo methylation (Brandeis et al., 1994). Macleod et al. (1994, 1998) have suggested that the presence of a functional element within the GC-rich domain maintains the methylation-free status. Accordingly, although the proximal promoter of the *MDR1* gene is important for regulating basal gene expression in normal human tissues, epigenetic status




Fig. 4. EMSA analysis with oligonucleotides corresponding to variants (A, T-1517aC; B, G-1459aA; C, T-1017aT; and D, C-145G and T-129C) in the *MDR1* gene promoter. The nuclear extracts (NE; 5 μ g of protein) from HepG2 cells were incubated with 32 P-labeled oligonucleotides. Specificity of nuclear protein binding was demonstrated by a 100-fold molar excess of unlabeled oligonucleotide. Data are representative of three similar experiments.




Fig. 5. A, location of CpG sites in the *MDR1* promoter region. The CpG sites are represented by short vertical bars. B, methylation status of individual sites of the *MDR1* promoter region and mRNA expression in placental tissues with the promoter haplotype 1/1 and 3435 C/C genotypes.

seems not to be associated with variability in the transcriptional activity of the *MDR1* gene.

In conclusion, we identified various variants in the promoter of the *MDR1* gene and investigated their effects on transcriptional activity and mRNA expression in the placenta. Among these variants, the promoter haplotypes containing T-1517aC, T-1017aC, and T-129C were particularly associated with high level of transcriptional activity and mRNA expression but independently of the coding SNP C3435T. Because these promoter haplotypes or SNPs are found at a relatively low frequency in Japanese and Caucasian populations, further study is needed to establish the impact of their allelic variants on drug disposition and responses in clinical situations. Interestingly, one study has shown a possibility of regulation by tissue-specific factors for the *MDR1* gene expression (Kohno et al., 1990). Also, Sundseth et al. (1997) have reported that an element just upstream of the Y box had opposite effects in different human carcinoma cell lines. Their results suggest that allelic variants in the promoter region of the *MDR1* gene contribute to the polymorphic expression of P-glycoprotein in a tissue-specific manner. Future studies may need to estimate the influence of *MDR1* promoter variants on transcriptional activity in various P-glycoprotein-expressing tissues.

Acknowledgments

We thank Makoto Taniguchi (Tottori University Faculty of Medicine) for technical support and advice.

References

Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, Beaune P, Legendre C, and Thervet E (2003) Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. *J Am Soc Nephrol* 14:1889-1896.

Brandeis M, Frank D, Keshetz I, Siegfried Z, Mendelsohn M, Nemes A, Temper V, Razin A, and Cedar H (1994) Sp1 elements protect a CpG island from de novo methylation. *Nature (Lond)* 371:435-438.

Calado RT, Falcao RP, Garcia AB, Gabellini SM, Zago MA, and Franco RF (2002) Influence of functional *MDR1* gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. *Haematologica* 87:564-568.

Cornwell MM and Smith DE (1993) SP1 activates the *MDR1* promoter through one of two distinct G-rich regions that modulate promoter activity. *J Biol Chem* 268:19505-19511.

Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, and Liggett SB (2000) Complex promoter and coding region 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. *Proc Natl Acad Sci USA* 97:10483-10488.

El-Osta A, Kanatharidis P, Zalberg JR, and Wolffe AP (2002) Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (*MDR1*) on activation. *Mol Cell Biol* 22:1844-1857.

Fromm MF (2002) The influence of *MDR1* polymorphisms on p-glycoprotein expression and function in humans. *Adv Drug Deliver Rev* 54:1295-1320.

Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, and Paul CL (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc Natl Acad Sci USA* 89:1827-1831.

Fryxell KB, McGee SB, Simoneaux DK, Willman CL, and Cornwell MM (1999) Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells. *Leukemia* 13:910-917.

Goldsmith ME, Madden MJ, Morrow CS, and Cowan KH (1993) A Y-box consensus sequence is required for basal expression of the human multidrug resistance (*mdr1*) gene. *J Biol Chem* 268:5856-5860.

Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmüller J, John A, Cassorbi I, Gerloff T, Roots I, Eichelbaum M, et al. (1999) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc Natl Acad Sci USA* 97:3473-3478.

Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, and Okumura K (2002) Significant genetic linkage of *MDR1* polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. *Pharm Res (NY)* 19:1581-1584.

Ieiri I, Tainaka H, Morita T, Hadama A, Mamiya K, Hayashibara M, Ninomiya H, Ohmori S, Kitada M, Tashiro N, et al. (2000) Catalytic activity of three variants (Ile, Leu and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. *Ther Drug Monit* 22:237-244.

Ishikawa T, Hirano H, Onishi Y, Sakurai A, and Tarui S (2004) Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. *Drug Metab Pharmacokinet* 19:1-14.

Jin S and Scotto KW (1993) Transcriptional regulation of the *MDR1* gene by histone acetyltransferase and deacetylase is mediated by NF-Y. *Mol Cell Biol* 13:4377-4384.

John A, Köpke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, et al. (2002) Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein *MDR1* gene. *Clin Pharmacol Ther* 72:584-594.

Jones PA and Takai D (2001) The role of DNA methylation in mammalian epigenetics. *Science (Wash DC)* 293:1068-1070.

Judson R, Stephens JC, and Windemuth A (2000) The predictive power of haplotypes in clinical response. *Pharmacogenomics* 1:15-26.

Kim RB and Tirona RG (2002) Pharmacogenomics of organic anion-transporting polypeptides (OATP). *Adv Drug Deliver Rev* 54:1343-1352.

Kohno K, Sato S, Uchiyama T, Takano H, Kato S, and Kuwano M (1990) Tissue-specific enhancer of the human multidrug-resistance (*MDR1*) gene. *J Biol Chem* 265:19690-19696.

Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryker D, Ferrin TE, Young JD, Taylor T, et al. (2003) Sequence diversity and haplotype structure in the human ABCB1(*MDR1*, multidrug resistance transporter) gene. *Pharmacogenetics* 13:481-484.

MacLeod D, Ali RR, and Bird A (1998) An alternative promoter in the mouse major histocompatibility complex class II I-A β gene: implications for the origin of CpG islands. *Mol Cell Biol* 18:4433-4443.

MacLeod D, Charlton J, Mullins J, and Bird AP (1994) Sp1 sites in the mouse *aprt* gene promoter are required to prevent methylation of the CpG island. *Genes Dev* 8:2282-2292.

Madden MJ, Morrow CS, Nakagawa M, Goldsmith ME, Fairchild CR, and Cowan KH (1993) Identification of 5' and 3' sequences involved in the regulation of transcription of the human *mdr1* gene in vivo. *J Biol Chem* 268:8290-8297.

Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, and Okumura K (2002) Effect of the mutation (C3435T) at exon 26 of the *MDR1* gene on expression level of *MDR1* messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. *Clin Pharmacol Ther* 71: 297-303.

- Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Oshima K, Kozuru M, Komatsu H, Ueda R, and Kuwano M (1998) Hypomethylation status of CpG sites at the promoter region and overexpression of the human *MDR1* gene in acute myeloid leukemias. *Blood* 92:4296-4307.
- Ogura M, Takatori T, and Tsuruo T (1992) Purification and characterization of NF-R1 that regulates the expression of the human multidrug resistance (*MDR1*) gene. *Nucleic Acids Res* 20:5811-5817.
- Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, et al. (2001) *MDR1* genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. *Pharm Res (NY)* 18:1400-1404.
- Singal R and Ginder GD (1999) DNA methylation. *Blood* 93:4059-4070.
- Sparreboom A, Danesi R, Ando Y, Chan J, and Figg WD (2003) Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. *Drug Resist Update* 6:71-84.
- Sundseth R, MacDonald G, Ting J, and King AC (1997) DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. *Mol Pharmacol* 51:963-971.
- Takane H, Ieiri I, and Otsubo K (2003) Genetic polymorphisms of organic anion and cation transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. *Curr Pharmacogenomics* 1:245-257.
- Takeuchi T, Nakamura S, Kayasuga A, Isa S, and Sato K (2000) Multiple elements for negative regulation of the rat catalase gene expression in dedifferentiated hepatoma cells. *J Biochem* 128:1025-1031.
- Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, et al. (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (*MDR*)-1 gene. *J Pharmacol Exp Ther* 297:1137-1143.
- Tang K, Ngoi SM, Gwee PC, Chua JMZ, Lee EJD, Chong SS, and Lee CGL (2002) Distinct haplotype profiles and strong linkage disequilibrium at the *MDR1* multidrug transporter gene locus in three ethnic Asian populations. *Pharmacogenetics* 12:437-450.
- Toda Y, Wada M, Kuroiwa K, Kinugawa N, Harada T, Nagayama J, Nakagawa M, Naito S, and Kuwano M (2000) *MDR1* gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. *Clin Cancer Res* 6:4618-4627.
- Ueda K, Pastan I, and Gottesman MM (1987) Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. *J Biol Chem* 262:17432-17436.
- van Groenigen M, Valentijn LJ, and Baas F (1993) Identification of a functional initiator sequence in the human *MDR1* promoter. *Biochim Biophys Acta* 1172: 138-146.

Address correspondence to: Dr. Hiroshi Takane, Department of Hospital Pharmacy, Faculty of Medicine, Tottori University, 36-1, Nishi-machi, Yonago, 683-8504, Japan. E-mail: takane@grape.med.tottori-u.ac.jp

Allelic expression imbalance of the human *CYP3A4* gene and individual phenotypic status

Takeshi Hirota¹, Ichiro Ieiri^{2,*}, Hiroshi Takane², Shinji Maegawa³, Masakiyo Hosokawa⁵, Kaoru Kobayashi⁵, Kan Chiba⁵, Eiji Nanba³, Mitsuo Oshimura⁴, Tetsuo Sato⁵, Shun Higuchi¹ and Kenji Otsubo²

¹Clinical Pharmacokinetics, Division of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 8128582, Japan, ²Department of Hospital Pharmacy, Faculty of Medicine, ³Division of Functional Genomics, Research Center for Bioscience and Technology and ⁴Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science, Tottori University, Yonago 6838504, Japan and ⁵Laboratory of Biochemical Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 2740816, Japan

Received August 6, 2004; Revised and Accepted September 20, 2004

The human cytochrome P450 3A4 (*CYP3A4*) plays a dominant role in the metabolism of numerous clinically useful drugs. Alterations in the activity or expression of this enzyme may account for a major part of the variation in drug responsiveness and toxicity. However, it is generally accepted that most of the known single nucleotide polymorphisms in the coding and 5'-flanking regions are not the main determinants for the large inter-individual variability of *CYP3A4* expression and activity. We show that the allelic variation is critically involved in determining the individual total hepatic *CYP3A4* mRNA level and metabolic capability. There exists a definite correlation between the total *CYP3A4* mRNA level and allelic expression ratio, the relative transcript level ratio derived from the two alleles. Individuals with a low expression ratio, exhibiting a large difference of transcript level between the two alleles, revealed extremely low levels of total hepatic *CYP3A4* mRNA, and thus low metabolic capability as assessed by testosterone 6 β -hydroxylation. These results present a new insight into the individualized *CYP3A4*-dependent pharmacotherapy and the importance of expression imbalance to human phenotypic diversity.

INTRODUCTION

Among the human cytochrome P450 (CYP) proteins, the members of the *CYP3A* subfamily occupy an important position owing to their abundance in liver and gut and to their collective large substrate spectrum (1). *CYP3A* proteins account for up to 50% of total CYP activity in the liver, and they metabolize up to 60% of all drugs currently in use (2,3). Cytochrome P450 3A4 (*CYP3A4*) is the major form of CYP in human liver; accounting for 30% of total CYP protein content (4). A wide inter-individual variation exists in *CYP3A4* activity as assessed by direct analysis of liver microsomes (4) and through the use of *in vivo* probe drugs (5). The basis of this variation is not yet understood but may be due to genetic factors. A clinical study with *CYP3A4* substrates suggested that ~60–90% of the inter-individual variability

in hepatic *CYP3A4* activity is genetically determined (6). The coding and 5'-flanking regions of the *CYP3A4* gene have been isolated and sequenced, and some single nucleotide polymorphisms (SNPs) have been identified; however, their allelic frequencies and/or the available functional experiments indicate a limited role for these variants in the inter-individual variability of *CYP3A4* expression and activity (7–12).

In addition to SNPs, various gene expression mechanisms have recently been reported to determine phenotypic variability; these patterns include genomic imprinting (13,14), X-chromosome inactivation (15) and other mechanisms (16,17). Among them, genomic imprinting is an epigenetic phenomenon where parental alleles are genetically marked, leading to the differential expression of paternal and maternal alleles in somatic cells (13,14). Imprinting genes are often clustered in chromosomal domains and are thought to

*To whom correspondence should be addressed at: Department of Hospital Pharmacy, Faculty of Medicine, Tottori University, Nishi-machi 36-1, Yonago 6838504, Japan. Tel: +81 859348385; Fax: +81 859348087; Email: ieiri@grape.med.tottori-u.ac.jp




Figure 1. Relationship between CYP3A4 phenotypes and CYP3A4 genotype in Caucasian livers. Open, partially filled and closed squares correspond to liver homozygous for the reference sequence (R), and heterozygous and homozygous for the variant sequence (V).

be coordinately regulated by imprinting control centers (13,18). Interestingly, three members of the CYP3A sub-family, CYP3A4, CYP3A5 and CYP3A7, are localized in tandem on the long arm of chromosome 7 at q21–q22.1 (19,20), where several imprinted genes are clustered (21). In addition, differences in expression levels between the two alleles of the same gene (i.e. preferential expression of one of the two alleles), which were not consistent with parental imprinting, have been reported in various genes such as PKD2, p73 and Calpain-10 (16,22). Some investigators indicated that such allelic variation in gene expression was common in the human genome (17,22). The individual allelic expression status may result in a change in the expression level of the gene (23,24), leading to phenotypic variability in the pharmacokinetic and pharmacodynamic outcomes of drug therapy. On screening the entire CYP3A4 gene, we found two common non-functional and racially independent intronic SNPs, C78013T (C → T at nt 78013) and C78649T (C → T at nt 78649), and used them as markers in subsequent gene expression analyses. Using these SNPs, we elucidated that the allelic variation is critically involved in

the hepatic CYP3A4 mRNA expression. Individuals with a low expression ratio, exhibiting a large difference of transcriptional level between the two alleles, revealed extremely low hepatic CYP3A4 levels and thereby reduced metabolic activity. These findings explain the substantial inter-individual differences in CYP3A4 expression and activity.

RESULTS

Screening of the marker SNPs for assessment of allelic variation

To screen the marker SNPs for assessment of allelic variation and to evaluate the presence of functional CYP3A4 gene variants, we amplified and sequenced the whole CYP3A4 gene, CYP3A4 5'-flanking region and 3'-untranslated region (UTR), spanning ~60 kb, using genomic DNAs extracted from eight Caucasian liver samples with high (HHL-6, -7, -14 and -26) or low (HHL-12, -17, -19 and -20) levels of total CYP3A4 mRNA (Fig. 1). The former and latter samples also indicated high and low testosterone 6β-hydroxylation

activity, respectively. In the present study, testosterone 6 β -hydroxylation capability was used as an index for individual CYP3A4 activity. We identified 4, 35 and 17 polymorphisms in the 5'-flanking region, 3'-UTR and intronic region, respectively, but did not find any coding SNPs. Although three samples, HHL-6, HHL-7 and HHL-17, had many SNPs in the regions analyzed, the other samples had only 2–4 SNPs. Among them, frequencies of the C78013T (8/8) and C78649T (4/8) polymorphisms were relatively high. Thus, we used these two intronic SNPs as markers in the subsequent gene expression study.

We next examined the association of the allelic pattern with total hepatic CYP3A4 mRNA levels. Although the CYP3A4 level was comparable between HHL-6 and HHL-26, the SNP patterns were clearly different. In contrast, there were remarkable differences in the CYP3A4 levels between HHL-7 and HHL-17 even though the SNP pattern was similar. In addition to the total mRNA levels, a similar trend was observed in the testosterone 6 β -hydroxylation activity. As has previously been demonstrated (7–12), these results suggest that SNPs in these regions are not involved in the large variability in the *CYP3A4* gene expression and metabolic activity.

Correlation between total hepatic CYP3A4 mRNA levels and CYP3A4 hnRNA levels

We next examined whether tissue levels of heterogeneous nuclear RNA (hnRNA), the unprocessed precursor of the mature, functional mRNA, can be used as a surrogate for gene transcription. CYP3A4 hnRNA and total mRNA levels were determined in a total of 18 hepatic samples. Quantification of total CYP3A4 mRNA and hnRNA was performed by the real-time PCR method. As shown in Figure 2, CYP3A4 mRNA showed significant regression ($r = 0.775$; $P < 0.001$). These results validated the use of CYP3A4 hnRNA as an estimate of CYP3A4 gene activity in human liver samples.

Allelic variations in human liver samples

Prior to evaluating the functional significance of allelic variation in total hepatic CYP3A4 mRNA levels and metabolic activity, we estimated allelic expression ratios, defined as a measure of the expression of the less-abundant allele divided by that of the more-abundant allele, in order to confirm inter-individual variation in the allelic expression of *CYP3A4*. As described in more detail in the Materials and Methods, allelic variation was determined on the basis of difference in band intensities between the two alleles using a fluorescence image analyzer. When an individual is heterozygous for a marker SNP, it is possible to detect the relative abundance of allelic transcripts. Generally, both copies of human autosomal genes are assumed to be co-dominantly expressed in equal proportions. The detection of allelic variation is based on a quantitative analysis of RNA transcripts in order to detect deviations from the expected equimolar ratio between two alleles in a heterozygous sample. After the screening of genomic DNA from all 40 Caucasian liver samples, it was possible to identify 18 individuals who were heterozygous for either the *MnlI* (C78013T) or *AciI* (C78649T) site.




Figure 2. Relationship of total CYP3A4 mRNA and hnRNA levels in human liver samples. A simple linear regression analysis was performed.

The difference in expression between the two alleles varied among samples (Fig. 3), and some of the 18 individuals had fractional allelic expression values lower than the 95% confidence interval for the mean (0.70 ± 0.20 ; 95% confidence interval, 0.60–0.80). Notably, the values in HHL-12 (0.28), HHL-16 (0.45), HHL-20 (0.46) and HHL-36 (0.49) were extremely low, being well outside the intervals, indicating monoallelic expression. Preferentially expressed allele in an individual sample was also shown in Figure 3. Predominantly expressed allele was different among samples, suggesting that both marker SNPs have no significant effects on the expression of the *CYP3A4* gene.

Allelic expression pattern in informative lymphoblasts

To determine whether the two alleles of the human *CYP3A4* gene are differentially expressed according to parental origin, we used reverse transcription–polymerase chain reaction (RT–PCR) of total RNA extracted from Epstein–Barr (EB) virus-transformed lymphoblasts, followed by PCR–RFLP. The parental origin of alleles expressed in children was identified by RFLP analysis. Lymphoblasts were obtained from a panel of 22 healthy Japanese individuals who were members of six distinct families. These samples allowed the precise determination of the parental origin of alleles in the heterozygous children. Of all the cases, two siblings were heterozygous for a polymorphism at either the *MnlI* site (C78013T in intron 7) or the *AfaI* site (G82266A in intron 10) (Fig. 4A). As the SNPs used here are in intronic regions of *CYP3A4*, the cDNA analyzed represents unspliced, hnRNA (25). Thus, all RT reactions in the present study included a negative control to ensure that genomic DNA did not contaminate the subsequent PCR. We firstly determined the parent's genotypes using genomic DNA samples. At the *MnlI* site (for C1 in Fig. 4B and C), although the maternal genotype was homozygous for the T78013 allele, the paternal genotype was heterozygous for the C78013 allele. At the *AfaI* site (for C2), the corresponding genotypes were homozygous for the G82266 allele and heterozygous for the A82266 allele, respectively. In the RT–PCR products, in contrast to C1, who showed a




Figure 3. Allelic expression ratio of the *CYP3A4* gene in Caucasian livers. The expression ratio (y-axis) was estimated on the basis of the average less-/more-abundant ratios (replicated data-points for each sample) at either the C78013T or the C78649T polymorphism, and corrected using the average genomic ratio. The shaded box represents ~95% confidence interval and the red bars indicate individuals displaying significant variation.

monoallelic maternal (T78013) expression, the sibling C2 showed a biallelic expression, but the paternal allele (A82266) was preferentially expressed.

It is interesting to know whether allelic variation is inherited. In order to address this issue, we further analyzed allelic expression patterns using paternal RT-PCR products, because paternal genotype was heterozygous for both polymorphic sites (at genomic DNA-based genotypes). As shown in Figure 4B, paternal alleles were inherited by the two siblings; the paternal inactive allele (i.e. unexpressed C78013 allele at the *MnII* site) and active allele (i.e. expressed A82266 allele at the *AfaI* site) were inherited by siblings C1 and C2, respectively. These results suggest that allelic variation is inherited, at least in B virus-transformed lymphoblasts.

Methylation status in the most proximal 5'-CpG island of the *CYP3A4* gene

We focused on the most proximal 5'-CpG island (covering ~450 bp), which is ~30 kb upstream of the translational start codon, and examined the association of the methylation status with total *CYP3A4* mRNA levels using six liver samples; samples HHL-6, -7 and -14 had high and HHL-12, -19 and -20 had low mRNA levels (Fig. 1). The percent methylation of the 31 CpG sites analyzed in the *CYP3A4* CpG island was calculated. Although differentially methylated CpG sites were found, most of the sites analyzed were largely methylated (Fig. 5). No clear association between the methylation status and total mRNA levels was observed.

Allelic variation and *CYP3A4* phenotypes

Correlations between the allelic expression ratio and phenotype indexes are shown in Figure 6. The total hepatic *CYP3A4* mRNA level correlated strongly with the allelic ratio (Fig. 6A; $r^2 = 0.786$, $P < 0.001$). Of these 18 samples, we could measure *CYP3A4* activity using testosterone as an enzyme-specific substrate in 10. As expected, 6 β -hydroxylation capability also correlated strongly with the

allelic ratio (Fig. 6B; $r^2 = 0.541$, $P < 0.05$). These results indicate that the individuals with a low ratio, who exhibited a large difference in hnRNA expression level between the two alleles, have extremely low total hepatic *CYP3A4* mRNA levels, and consequently poor metabolic capability.

Frequency of the two marker SNPs in different racial populations

We determined frequencies of heterozygous carriers for C78013T and C78649T polymorphisms, which were relatively common among the eight liver samples, using genomic DNA from three racial populations (Table 1). We found that the frequency of heterozygous carriers of the C78013T allele in Caucasians was 0.35; in Japanese, 0.39; and in African Americans, 0.56. The corresponding values for the C78649T allele were 0.21, 0.16 and 0.36, respectively. When excluding individuals having two SNPs simultaneously, 50.0% of Caucasians, 41.7% of Japanese and 61.5% of African Americans were heterozygous for either SNP.

DISCUSSION

Variations in gene sequence and expression underlie much of human variability. To decide individual gene expression status, we first sequenced the whole *CYP3A4* gene, *CYP3A4* 5'-flanking region and 3'-UTR using liver tissues from eight Caucasians, and then examined the association of SNP patterns with total *CYP3A4* mRNA levels and testosterone 6 β -hydroxylation capability. Although the observed nucleotide diversity in the *CYP3A4* promoter was 1 in 7246 bp in Caucasians (26), two recent reports provided evidence for the existence of a specific *cis*-acting element, 8000 bp distal to the transcription start point, which plays an important role in the transcriptional induction of *CYP3A4* (27,28). Thus, we analyzed the *CYP3A4* 5'-flanking region, spanning 8 kb. As has been expected, none of the SNPs in these regions was clearly associated with differences in *CYP3A4* levels and metabolic capability. These findings raise the possibility




Figure 4. Identification of allelic variation of the *CYP3A4* gene. (A) Schematic of the PCR-RFLP for the three polymorphisms. Black squares denote *CYP3A4* exons. Locations of PCR primers are indicated by arrows. Predicted RFLP products of each polymorphism are drawn below the schematic. (B) Actual expression patterns in lymphoblasts obtained from two informative siblings. (C) Validation of the allelic variation by sequencing.

that other mechanisms such as an epigenetic gene alteration affect *CYP3A4* levels more frequently than SNPs (7–12).

In the present study, we used unspliced hnRNA as the template and used intronic SNPs as the marker to assess the allelic variation, because there were no exonic SNPs that can be used

to test for allelic variation in mRNA levels. Thus, we secondarily examined whether tissue levels of hnRNA, the unprocessed precursor of the mature, functional mRNA, can be used as a surrogate for gene transcription. To ensure precise determinations for hnRNA and mRNA levels separately,




Figure 5. Methylation analysis of the CpG island of the *CYP3A4* gene. Bisulfite PCR products were subcloned and sequenced. The degree of methylation on each CpG dinucleotide was obtained from 20 individual clones. Open and closed areas represent unmethylated and methylated CpG dinucleotides, respectively.




Figure 6. Allelic expression ratio and *CYP3A4* phenotypes in Caucasian livers. (A) Relationship between total mRNA level (y-axis) and allelic ratio. The ratio was estimated based on the average less-/more-abundant ratios at either the C78013T or the C78649T polymorphism. (B) Relationship between testosterone 6β-hydroxylation capability and allelic ratio. The numbers are identical with the sample numbers in Figures 1 and 3. (C) Actual expression patterns in the livers.

we have designed intron- and exon-specific oligonucleotide primers, respectively. As shown in Figure 2, the two exhibited a significant correlation. These results validated the use of *CYP3A4* hnRNA as an estimate of *CYP3A4* gene activity in human liver samples, and suggest that total *CYP3A4* mRNA levels are controlled at a point upstream of the precursor by the transcriptional generation of hnRNA (29,30).

Recently, in order to determine allelic variation, an allele-specific quantitative PCR method with allele-specific probes has been developed. Such an analytical method provides the direct expression level of each allele separately by measuring the fluorescent intensity (22,31). In the present study, we had also tried to develop a real-time quantitative PCR method; however, we were unsuccessful owing to a technical limitation,

Table 1. Heterogeneous carriers for *CYP3A4* mutations in different racial populations

Position	Reference allele (R)	Variant allele (V)	Population	Genotype			Frequency of heterogeneous carriers
				R/R	R/V	V/V	
78013	ctgcCtcta	ctgcTtcta	Caucasian	8	34	54	0.35 (0.25–0.45)
			Japanese	6	37	53	0.39 (0.29–0.49)
			African American	9	54	33	0.56 (0.46–0.66)
78649	gtagCggtg	gtagTggtg	Caucasian	74	20	2	0.21 (0.13–0.29)
			Japanese	80	15	1	0.16 (0.09–0.23)
			African American	4	35	56	0.36 (0.26–0.46)

Values in parentheses indicate 95% confidence interval.

low expression levels of *CYP3A4* hnRNA, especially in samples indicating monoallelic expression. Thus, we determined allelic variations on the basis of difference of band intensities between the two alleles using a fluorescence image analyzer. With such an analytical method, in addition to DNA contamination, splicing variants are drawbacks for the accurate estimation of allelic variation. In the *CYP3A4* gene, one variant, *CYP3A4*6*, with an insertion of adenine at position 17776, has been reported to create premature mRNA because the variant causes a frame shift and an early stop codon in exon 9 (32). However, the *CYP3A4*6* variant was not observed in our liver samples (data not shown), and this finding was in keeping with previous reports that it has not been observed in Caucasian populations (33,34).

Differential allelic gene expression resulting from genomic imprinting has been a focus of cancer research. Among known imprinted genes, the Wilms' tumor suppressor gene (*WT1*) has been reported to exhibit a unique allele-specific expression profile (35); cultured human fibroblasts and lymphocytes showed a paternal or biallelic expression of *WT1* in some cases, whereas a maternal or biallelic expression was observed in human placental villi and fetal brain tissue (36,37). These results suggest that the allele-specific expression profile (e.g. allele switching) of certain genes depends on the tissue source. Indeed, although somatic allele switching is not a common feature of imprinted genes, this unusual phenomenon is also observed in human *H19* (38) and *IMPT1* (39) genes. However, in the present study, the degree of difference in the expression between the two alleles varied among samples, and large variations were observed in only a minority of samples (Fig. 3). In addition, informative lymphoblast samples indicated opposite-directional expression; both paternal and maternal preferential expressions were observed in the two siblings (Fig. 4). Thus, taking these findings into consideration, it is feasible that, at least in human liver, *CYP3A4* is not an imprinting gene.

Although allelic variation in gene expression is common in the human genome (17,22), its pharmacokinetic and pharmacodynamic significance has not been reported. One study has demonstrated that the allelic variation in *APC* gene expression plays a critical role in colon cancer (16). The present study, however, is the first to demonstrate that variations in *CYP3A4* phenotypes are caused by changes in allelic expression levels. The strong correlation between the allelic ratio and phenotypic indexes (e.g. total hepatic mRNA level and testosterone 6 β -hydroxylation activity) indicates that

individuals having low ratios, who exhibit a large difference in hnRNA expression levels between the two alleles, have extremely low levels of total *CYP3A4* mRNA and thereby reduced metabolic activity. Human *CYP3A* activity reflects the heterogeneous expression of at least two *CYP3A* family members, *CYP3A4* and *CYP3A5*. Although the role of *CYP3A5* in testosterone 6 β -hydroxylation *in vivo* has not been defined (40), this heterogeneity is a possible reason for the lower correlation observed between the allelic ratio and hydroxylation activity.

Although not much is known about mechanisms regulating the constitutive basal expression of the *CYP3A4* gene in human tissues, currently available data indicate that numerous transcriptional factors such as hepatocyte nuclear factor-1 (HNF-1), HNF-2, HNF-4 and CCAAT/enhancer-binding protein (C/EBP) regulate the constitutive expression of *CYP* genes (41). Liver-enriched transcription factors C/EBP and HNF-3 γ , which are involved in the regulation of numerous liver-specific genes (42), *trans*-activate and cooperatively regulate hepatic-specific *CYP3A4* gene expression (43,44). Because these liver-enriched *trans*-activating factors play an important role in the constitutive expression of *CYP3A4*, variations in their expression could ultimately be responsible for the different expression levels of *CYP3A4* found in various human tissues; *CYP3A4* is expressed primarily in liver and intestine and at very low and physiologically insignificant levels in lymphoblasts (45). Although transcriptional elements in lymphoblasts are suggestive of a limited expression (low or absent), allelic variation was clearly observed in lymphoblasts as well as in liver samples (Figs 4 and 6). Thus, these results suggest that it is unlikely that the transcriptional elements described earlier are involved in the allelic imbalance.

Initially in the present study, we could not find any functional SNPs in the *CYP3A4* gene. These results suggest that the post-transcriptional regulation of *CYP3A4* gene expression is likely to be similar for both alleles. As a majority of the differentially expressed genes have a virtually identical sequence in their mRNAs (46), transcriptional initiation by *cis*-acting components is one of the most important controls in regulating the variation in allelic gene expression. The deviation of allelic variation varied among samples (Fig. 3), which also suggests that the variation could result from the allelic heterogeneity of one or more *cis*-acting regulatory polymorphisms (47) or from epigenetic factors such as DNA methylation (48) and the existence of non-coding RNAs (49). In this regard, we examined methylation status in the CpG island,

which is ~30 kb upstream of the translational start codon, using six Caucasian liver samples with high and low levels of total CYP3A4 mRNA by cloning and sequencing bisulfite-treated DNA. However, unfortunately, we did not observe allele-specific differential methylation (Fig. 5).

Recently, Lo *et al.* (22) reported that 326 of 602 genes showed a preferential expression of one allele, and 170 of those showed greater than a 4-fold difference between the two alleles. Interestingly, some of the genes that showed a skewed allelic expression were located next to each other (i.e. clustered), and a subset of these genes is located in known imprinting domains. *ASB4*, *DLX5*, *SGCE* and *PEG10*, which have previously been reported to be imprinted, are located in the imprinting domain at 7q21–q31 (21). The human *CYP3A* genes, *CYP3A43*, *CYP3A4*, *CYP3A7* and *CYP3A5*, consist of a cluster spanning 231 kb within this domain, at 7q21–q22.1 (19,20). In addition, two *CYP3A* pseudogenes are formed in two intergenic regions (*CYP3A4–CYP3A7* and *CYP3A7–CYP3A5*) (50). These unique gene-structural features suggest that the allelic variation in hepatic CYP3A4 expression can be attributed to unknown non-coding RNA(s). The paternally expressed non-coding RNA (*Air* RNA) overlapping one of three imprinted, maternally expressed protein-coding genes (*Igf2r/Slc22a2/Slc22a3*) has been reported to play an important role in repression of all three genes on the paternal expression (49). Nevertheless, we cannot exclude the possibility that the *cis*-acting regulatory polymorphisms (47) responsible for the change in CYP3A4 expression reside far up- and downstream of the gene of the affected allele. Indeed, Wojnowski and Brockmoller (51) have recently indicated a hepatic transcriptional imbalance of the *CYP3A5* gene in *CYP3A5*1A*/*3 heterozygous samples, and the *cis*-acting *1A variant, which increases the expression of the *CYP3A5* gene transcript from the allele carrying the variant, is a possible mechanism for the imbalance.

One report provided evidence that allelic variation can be transmitted by Mendelian inheritance (16). As shown in Fig. 4B, our results indicated that the allelic variation of *CYP3A4* expression was also inherited, as has been observed in the genes *Calpain-10* and *PKD2* (16). Yan *et al.* (16) identified three informative families and found that altered expression of the genes *CAPN10* and *PKD2* was consistently inherited with a single haplotype defined by at least two adjacent microsatellite markers. In contrast to the findings by Yan *et al.* (16), although the allelic variation of *CYP3A4* expression was consistent with Mendelian inheritance, allelic expression ratio appeared to be independent from genotypes. In the present study, we had tried to find the useful haplotypes within the regions we had analyzed; however, we were unsuccessful owing to large inter-individual variability in the SNP pattern (Fig. 1). The mechanism that generates allelic variation between two alleles remains unclear. However, as the expression of *CYP3A4* is unlikely to be regulated by imprinting, these results also suggest the existence of unknown, unidentified *cis*-acting inherited variations influencing gene expression. If *cis*-acting inherited variations in gene expression are common among normal populations, an insight into how this occurs in individuals may help us to understand the large variability in CYP3A4 phenotypes.

MATERIALS AND METHODS

Population samples

We examined allelic frequencies of C78013T and C78649T mutations in genomic DNA samples from unrelated Caucasian, Japanese and African American volunteers (96 subjects each) (Tennessee Blood Services, Memphis, TN, USA). We also obtained samples from the following sources: 22 lymphoblast samples for which the parental origin of the *CYP3A4* alleles was determined (35); 18 livers (selected from 40 Caucasian donors, National Disease Research Interchange, Philadelphia, PA, USA) for which allelic expression variations and total hepatic CYP3A4 mRNA and hnRNA levels were determined, and 10 of the 18 liver samples in which testosterone 6 β -hydroxylation capabilities had been analyzed. We sequenced the *CYP3A4* gene, 5'-flanking region and 3'-UTR in eight of the 18 liver samples whose total CYP3A4 mRNA and hnRNA levels had been determined. We also determined methylation status in six of the 18 liver samples. EB virus-transformed lymphoblast cultures were obtained using standard procedures. This study was approved by the Ethical Board of the Faculty of Medicine, Tottori University and informed consent was obtained from all individuals.

Primers and sequencing

We designed 72 primer sets based on a published sequence (GenBank accession no. AF280107.1) to amplify the *CYP3A4* gene, *CYP3A4* 5'-flanking region and 3'-UTR; the amplicons were ~900 bp long (sequence available on request). Primer pairs were used for 30–40 cycles to amplify genomic DNA. The following conditions were used in each cycle: 95°C for 40 s, 52°C for 45 s, and 72°C for 1 min. PCR products were sequenced either directly or after subcloning using BigDye Terminator (Applied Biosystems, Foster City, CA, USA) sequencing. The sequencing primers were those used in the PCR amplifications. The sequence of both strands was analyzed for products from at least two independent PCR amplifications to ensure that the identified mutations were not PCR-induced artifacts.

cDNA synthesis

Total RNA was extracted with an RNAeasy Kit (Qiagen, Hilden, Germany) from EB virus-transformed lymphoblasts and liver samples. Prior to RT, total RNA samples were first treated with RNase-free DNase I, and then digested with *Hae*III and *Mbo*II (Takara, Kyoto, Japan). *Hae* III and *Mbo*II digest the potential DNA template which would lead to the amplification of both alleles and thus mask allelic variation. The RNA samples were then reverse-transcribed into first strand cDNA with 1 μ g of total RNA, 4 μ l of 5 \times first strand buffer, 4 μ l of 0.1 mM DTT, 1 μ l of 500 μ g/ml random primer (Promega, Madison, WI, USA), 4 μ l of 10 mM dNTP mixture and 200 U of SuperScript II RNase H⁻ reverse transcriptase (Life Technologies, Rockville, MD, USA). The reaction was incubated at 42°C for 60 min. RT reactions were always carried out in the presence or absence of reverse transcriptase to ensure that genomic DNA did

not contaminate the subsequent PCR. In all experimental procedures, no amplification was detected in the absence of RT, excluding DNA contamination.

Assessment of allelic variation (estimation of allelic expression ratio)

To assess allele-specific expression of *CYP3A4*, an *MnII* RFLP and an *AciI* RFLP in intron 7 (for liver samples), and an *MnII* RFLP in intron 7 and an *AfaI* RFLP in intron 10 (for lymphoblast samples) were analyzed. Primer sequences for cDNA amplification were as follows: *MnII* RFLP, 5'-TATCAG CCCCTGTCACAAAC-3' (forward) and 5'-TTCATGCCA CAACATAGTAAA-3' (reverse); *AciI* RFLP, 5'-CAATAGA TAAAGGCAAAGAGA-3' (forward) and 5'-GAAAGACTG CTGTAGGAAAAA-3' (reverse); *AfaI* RFLP, 5'-GCAGTG TTCTCTCCTTCATTATGTA-3' (forward) and 5'-CTAT GTTTCTTTCTTTTCTTTTCA-3' (reverse). All PCR products contain either a *HaeIII* or *MboII* restriction site. PCR was carried out under the same conditions for the screening of the variants, but only for 24–30 cycles. RFLP products were electrophoresed on a 3% agarose gel, then stained with SYBR green I (Takara). The relative expression of each allele was quantified on the basis of the difference in band intensities between the two alleles with a fluorescence image analyzer (Hitachi, Tokyo, Japan) using Analysis Version 6.0 software. As a control, genomic DNA PCR–RFLP products were included and ratios of the allele-specific band intensities were taken as a 1:1 allelic representation. In order to eliminate sampling or measurement error, we conducted the experiment for each sample with three replicates.

Methylation analysis

The methylation status of the CpG island which is ~30 kb upstream of the translational start codon (nt 36441–36896, GenBank accession no. AF280107), was confirmed by the bisulfite sequencing method (52). DNA was treated with sodium bisulfite using a CpGenome DNA modification kit (Intergen, Purchase, NY, USA) according to the manufacturer's instructions. PCR was performed in a total volume of 25 μ l consisting of 50 ng of bisulfite modified genomic DNA, 0.625 U of DNA polymerase and 0.25 μ M of each primer; 5'-GGGTTTATTTAGTTTGAGTTT-3' (forward) and 5'-TAACCCCTCTCTACATTCTAT-3' (reverse). After an initial denaturation at 95°C for 9 min, 43 cycles of 40 s at 95°C, 45 s at 52°C and 1 min at 72°C, as well as a final extension for 5 min at 72°C, were performed. The PCR product was cloned into the pGEM-T easy vector (Promega, Madison, WI, USA) then transformed into JM-109 (Promega), and plasmid DNA was collected by QIAprep Spin Mini-prep kit (Qiagen). The CpG methylation status of individual DNA strands was determined on the basis of a comparison with the sequence obtained from the genomic DNA without the addition of bisulfite modifications. Percent methylation of each site was determined by dividing the number of methylated CpGs at a specific site by the total number of clones analyzed ($n = 20$ in all cases).

Quantitative real-time PCR

Quantification of total hepatic *CYP3A4* mRNA and hnRNA was performed by real-time PCR detection using an ABI PRISM 7700 sequence detector (Applied Biosystems) with SYBR green detection of amplification products. Amplification mixtures contained 12.5 μ l of 2 \times SYBR green I Universal PCR Mix (Applied Biosystems), 0.5 μ l of cDNA synthesis mixture, 5 pmol each of the forward and reverse primers and distilled water in a total volume of 25 μ l. All primers were designed using the PrimerExpress program (Applied Biosystems). Primers for *CYP3A4* mRNA were directed to a sequence that spans the junction of exons 12 and 13, corresponding to open reading frame 1405–1465; 5'-AAAGAAAC ACAGATCCCCCTGAA-3' (forward) and 5'-CGGGTTTTTC TGGTTGAAGAAGT-3' (reverse). *CYP3A4* hnRNA primers were directed to a sequence located at bases +2253 to +2351 within intron 12 of the *CYP3A4* gene sequence; 5'-CACAGG TTTCCATGAATTTGTCT-3' (forward) and 5'-AAGATTGG ACAGTGAGAGCATTTC-3' (reverse). The copy number of the transcript was measured against a copy-number standard curve of cloned target templates consisting of serial 10-fold dilution points. β_2 -Microglobulin mRNA was used as the reference message for both *CYP3A4* mRNA and hnRNA.

Testosterone 6 β -hydroxylation capability in human liver samples

All incubations were performed in duplicate in solutions containing potassium phosphate (0.1 M, pH 7.4) and human liver microsomes (0.05 mg). Testosterone (final concentration, 30 μ M) was added to the incubation mixture at a final methanol concentration of 1%, and the mixtures were incubated at 37°C for 10 min. We added a NADPH-generating system to initiate the reaction. Reactions were terminated by the addition of 100 μ l of ice-CH₃CN. We used high-performance liquid chromatography (HPLC) to measure the quantities of extracted compounds (53).

ACKNOWLEDGEMENTS

This study was supported by RR2002, Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports and Technology, and Health and Labour Science Research Grants (Research on Advanced Medical Technology) from The Ministry of Health, Labour and Welfare, Tokyo, Japan.

REFERENCES

- Thummel, K.E. and Wilkinson, G.R. (1998) *In vitro* and *in vivo* drug interactions involving human CYP3A. *Annu. Rev. Pharmacol. Toxicol.*, **38**, 389–430.
- Li, A.P., Kaminski, D.L. and Rasmussen, A. (1995) Substrates of human hepatic cytochrome P450 3A4. *Toxicology*, **104**, 1–8.
- Evans, W.E. and Relling, M.V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. *Science*, **286**, 487–491.
- Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F.P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J. Pharmacol. Exp. Ther.*, **270**, 414–423.

5. Lown, K.S., Thummel, K.E., Benedict, P.E., Shen, D.D., Turgeon, D.K., Berent, S. and Watkins, P.B. (1995) The erythromycin breath test predicts the clearance of midazolam. *Clin. Pharmacol. Ther.*, **57**, 16–24.
6. Ozdemir, V., Kalowa, W., Tang, B.K., Paterson, A.D., Walker, S.E., Endrenyi, L. and Kashuba, A.D. (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. *Pharmacogenetics*, **10**, 373–388.
7. Rebbeck, T.R., Jaffe, J.M., Walker, A.H., Wein, A.J. and Malkowicz, S.B. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. [Erratum (1999) *J. Natl Cancer Inst.*, **91**, 1082.] *J. Natl Cancer Inst.*, **90**, 1225–1229.
8. Ball, S.E., Scatina, J., Kao, J., Ferron, G.M., Fruncillo, R., Mayer, P., Weinryb, I., Guida, M., Hopkins, P.J., Warner, N. *et al.* (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. *Clin. Pharmacol. Ther.*, **66**, 288–294.
9. Westlind, A., Lofberg, L., Tindberg, N., Andersson, T.B. and Ingelman-Sundberg, M. (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. *Biochem. Biophys. Res. Commun.*, **259**, 201–205.
10. Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V.P., Zheng, W., Raunio, H., Crespi, C.L. and Gonzalez, F.J. (2000) CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity. *Clin. Pharmacol. Ther.*, **67**, 48–56.
11. Wandel, C., Witte, J.S., Hall, J.M., Stein, C.M., Wood, A.J. and Wilkinson, G.R. (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism. *Clin. Pharmacol. Ther.*, **68**, 288–294.
12. Eiselt, R., Domanski, T.L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., Zanger, U.M., Brockmoller, J., Klenk, H.P., Meyer, U.A. *et al.* (2001) Identification and functional characterization of eight CYP3A4 protein variants. *Pharmacogenetics*, **11**, 447–458.
13. Brannan, C.I. and Bartolomei, M.S. (1999) Mechanisms of genetic imprinting. *Curr. Opin. Genet. Dev.*, **9**, 164–170.
14. Constancia, M., Pickard, B., Kelsey, G. and Reik, W. (1998) Imprinting mechanisms. *Genet. Res.*, **8**, 881–900.
15. Cooper, D.W., Johnston, P.G., Watson, J.M. and Graves, J.A.M. (1993) X-inactivation in marsupials and monotremes. *Semin. Dev. Biol.*, **4**, 117–128.
16. Yan, H., Yuan, W., Velculescu, V.E., Vogelstein, B. and Kinzler, K.W. (2002) Allelic variation in human gene expression. *Science*, **297**, 1143.
17. Pastinen, T., Sladek, R., Gurd, S., Sammak, A., Ge, B., Lepage, P., Lavergne, K., Villeneuve, A., Gaudin, T., Brandstrom, H. *et al.* (2004) A survey of genetic and epigenetic variation affecting human gene expression. *Physiol. Genomics*, **16**, 184–193.
18. Horike, S., Mitsuya, K., Meguro, M., Kotobuki, N., Kashiwagi, A., Notsu, T., Schulz, T.C., Shirayoshi, Y. and Oshimura, M. (2000) Targeted disruption of the human LIT1 locus defines a putative imprinting control element playing an essential role in Beckwith–Weidemann syndrome. *Hum. Mol. Genet.*, **9**, 2075–2083.
19. Brooks, B.A., McBride, O.W., Dolphin, C.T., Farrall, M., Scambler, P.J., Gonzalez, F.J. and Idle, J.R. (1988) The gene CYP3 encoding P450_{pncl} (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen type 1 alpha on 7q21–q22.1. *Am. J. Hum. Genet.*, **43**, 280–284.
20. Spurr, N.K., Gough, A.C., Stevenson, K. and Wolf, C.R. (1989) The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22–qter. *Hum. Genet.*, **81**, 171–174.
21. Okita, C., Meguro, M., Hoshiya, H., Haruta, M., Sakamoto, Y.K. and Oshimura, M. (2003) A new imprinted cluster on the human chromosome 7q21–q31, identified by human–mouse monochromosomal hybrids. *Genomics*, **81**, 556–559.
22. Lo, H.S., Wang, Z., Hu, Y., Yang, H.H., Gere, S., Buetow, K.H. and Lee, M.P. (2003) Allelic variation in gene expression is common in the human genome. *Genome Res.*, **13**, 1855–1862.
23. Reik, W. and Walter, J. (1998) Imprinting mechanisms in mammals. *Curr. Opin. Genet. Dev.*, **8**, 154–164.
24. Tilghman, S.M. (1999) The sins of the fathers and mothers: genomic imprinting in mammalian development. *Cell*, **96**, 185–193.
25. Evans, H.K., Wylie, A.A., Murphy, S.K. and Jirtle, R.L. (2001) The neuronatin gene resides in a 'micro-imprinted' domain on human chromosome 2–q11.2. *Genomics*, **77**, 99–104.
26. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P.B., Daly, A., Wrighton, S.A., Hall, S.D. *et al.* (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nat. Genet.*, **27**, 383–391.
27. Tirona, R.G., Lee, W., Leake, B.F., Lan, L.B., Cline, C.B., Lamba, V., Parviz, F., Duncan, S.A., Inoue, Y., Gonzalez, F.J., Schuetz, E.G. and Kim, R.B. (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. *Nat. Med.*, **9**, 220–224.
28. Goodwin, B., Hodgson, E. and Liddle, C. (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. *Mol. Pharmacol.*, **56**, 1329–1339.
29. Johnson, R.F., Mitchell, C.M., Giles, W.B., Walters, W.A. and Zakar, T. (2002) The *in vivo* control of prostaglandin H synthase-2 messenger ribonucleic acid expression in the human amnion at parturition. *Clin. Endocrinol. Metab.*, **87**, 2816–2823.
30. Johnson, R.F., Mitchell, C.M., Giles, W.B., Walters, W.A. and Zakar, T. (2003) The control of prostaglandin endoperoxide H-synthase-2 expression in the human chorion laeve at term. *J. Soc. Gynecol. Investig.*, **10**, 222–230.
31. Weber, M., Hagege, H., Lutfalla, G., Dandolo, L., Brunel, C., Cathala, G. and Fome, T. (2003) A real-time polymerase chain reaction assay for quantification of allele ratios and correction of amplification bias. *Anal. Biochem.*, **320**, 252–258.
32. Hsieh, K.P., Lin, Y.Y., Cheng, C.L., Lai, M.L., Lin, M.S., Siest, J.P. and Huang, J.D. (2001) Novel mutations of CYP3A4 in Chinese. *Drug Metab. Dispos.*, **29**, 268–273.
33. Eap, C.B., Buclin, T., Hustert, E., Bleiber, G., Golay, K.P., Aubert, A.C., Baumann, P., Telenti, A. and Kerb, R. (2004) Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. *Eur. J. Clin. Pharmacol.*, **60**, 231–236.
34. Garcia-Martin, E., Martinez, C., Pizarro, R.M., Garcia-Gamito, F.J., Gullsten, H., Raunio, H. and Agundea, J.A. (2002) CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. *Clin. Pharmacol. Ther.*, **71**, 196–204.
35. Mitsuya, K., Sui, H., Meguro, M., Kugoh, H., Jinno, Y., Niikawa, N. and Oshimura, M. (1997) Paternal expression of *WT1* in human fibroblasts and lymphocytes. *Hum. Mol. Genet.*, **6**, 2243–2246.
36. Jinno, Y., Yun, K., Nishiwaki, K., Kubota, T., Ogawa, O., Reeve, A.E. and Niikawa, N. (1994) Mosaic and polymorphic imprinting of the *WT1* gene in humans. *Nat. Genet.*, **6**, 305–309.
37. Nishiwaki, K., Niikawa, N. and Ishikawa, M. (1997) Polymorphic and tissue-specific imprinting of the human Wilms tumor gene, *WT1*. *Jpn J. Hum. Genet.*, **42**, 205–211.
38. Schweifer, N., Valk, P.J., Delwel, R., Cox, R., Francis, F., Meier-Ewert, S., Lehrach, H. and Barlow, D.P. (1997) Characterization of the C3 YAC contig from proximal mouse chromosome 17 and analysis of allelic expression of genes flanking the imprinted *Igf2r* gene. *Genomics*, **43**, 285–297.
39. Dao, D., Frank, D., Qian, N., O'Keefe, D., Vosatka, R.J., Walsh, C.P. and Tycko, B. (1998) *IMPT1*, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes. *Hum. Mol. Genet.*, **7**, 597–608.
40. Sy, S.K., Ciaccia, A., Li, W., Roberts, E.A., Okey, A., Kalow, W. and Tang, B.K. (2002) Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. *Eur. J. Clin. Pharmacol.*, **58**, 357–365.
41. Gonzales, F. and Lee, Y. (1996) Constitutive expression of hepatic cytochrome P450 genes. *FASEB J.*, **10**, 1112–1117.
42. Wang, J.C., Stafford, J.M., Scott, D.K., Sutherland, C. and Granner, D.K. (2000) The molecular physiology of hepatic nuclear factor 3 in the regulation of gluconeogenesis. *J. Biol. Chem.*, **275**, 14717–14721.
43. Ourlin, J.C., Jounaidi, Y., Maurel, P. and Vilarem, M.J. (1997) Role of the liver-enriched transcription factors C/EBP alpha and DBP in the expression of human CYP3A4 and CYP3A7. *J. Hepatol.*, **26** (Suppl. 2), 54–62.
44. Rodriguez-Antona, C., Bort, R., Jover, R., Tindberg, N., Ingelman-Sundberg, M., Gomez-Lechon, M.J. and Castell, J.V. (2003) Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. *Mol. Pharmacol.*, **63**, 1180–1189.

45. Burk, O. and Wojnowski, L. (2004) Cytochrome P450 3A and their regulation. Naunyn. Schmiedebergs. *Arch. Pharmacol.*, **369**, 105–124.
46. Yan, H. and Zhou, W. (2004) Allelic variations in gene expression. *Curr. Opin. Oncol.*, **16**, 39–43.
47. Hardison, R.C., Oeltjen, J. and Miller, W. (1997) Long human–mouse sequence alignments reveal novel regulatory elements: a reason to sequence the mouse genome. *Genome Res.*, **7**, 959–966.
48. Jaenisch, R. and Bird, A. (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat. Genet.*, **33**, S245–S254.
49. Sleutels, F., Zwart, R. and Barlow, D.P. (2002) The non-coding Air RNA is required for silencing autosomal imprinted genes. *Nature*, **415**, 810–813.
50. Finta, C. and Zaphiropoulos, P.G. (2000) The human cytochrome P450 3A locus. Gene evaluation by capture of downstream exons. *Gene*, **260**, 13–23.
51. Wojnowski, L. and Brockmoller, J. (2004) Single nucleotide polymorphism characterization by mRNA expression imbalance assessment. *Pharmacogenetics*, **14**, 267–269.
52. Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F., Grigg, G.W., Molloy, P.L. and Paul, C.L. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. *Proc. Natl Acad. Sci. USA*, **89**, 1827–1831.
53. Yoshimoto, K., Echizen, H., Chiba, K., Tani, M. and Ishizaki, T. (1995) identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-*N*-desisopropylation is mediated mainly by CYP1A2. *Br. J. Clin. Pharmacol.*, **39**, 421–431.

SNP Communication

A Novel Single Nucleotide Polymorphism (SNP) of the CYP2C19 Gene in a Japanese Subject with Lowered Capacity of Mephobarbital 4'-Hydroxylation

JUN MORITA¹, KAORU KOBAYASHI*¹, ATSUKO WANIBUCHI², MIYUKI KIMURA²,
SHIN IRIE², TAKASHI ISHIZAKI³, and KAN CHIBA¹

¹Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences,
Chiba University, Chiba, Japan

²Kyushu Pharmacology Research Clinic, Fukuoka, Japan

³Department of Pharmacology and Therapeutics, Graduate School of Medical and
Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan

Full text of this paper is available at <http://www.jssx.org>

Summary: We sequenced all nine exons and exon-intron junctions of the cytochrome P450 2C19 (*CYP2C19*) gene from a Japanese subject with a lowered capacity of CYP2C19-mediated 4'-hydroxylation after an oral administration of mephobarbital. We found a novel single nucleotide polymorphism (SNP) of *CYP2C19* gene as follows: SNP, 040110MoritaJ001; GENENAME: *CYP2C19*; ACCESSION NUMBER: NT_030059.8; LENGTH; 25 bases; 5'-GAGGGCCTGGCCC/TGCATGGAGCTGT-3'. The SNP (168946C>T) induced an amino acid alteration (Arg442Cys) located in exon 9 close to the heme-binding region of CYP2C19, which may result in the decrease in the catalytic properties of CYP2C19. A new allele having this SNP was designated as *CYP2C19*16*.

Key words: *CYP2C19*; novel SNP; amino acid substitution; Japanese

Introduction

Mephobarbital is metabolized to 4'-hydroxymephobarbital by CYP2C19 in human liver microsomes.¹⁾ Recently, we investigated the pharmacokinetic disposition and metabolism of mephobarbital in extensive metabolizers and poor metabolizers of CYP2C19 recruited from a Japanese population. Through the study, we found that a heterozygote of defective allele, *CYP2C19*2*, had a lower capacity for the 4'-hydroxylation of mephobarbital compared with the other heterozygotes. Urinary excretion rate of 4'-hydroxymephobarbital collected in 0 to 24 hours after an oral

administration of mephobarbital in the subject was only one third of those in the other heterozygotes of defective alleles, *CYP2C19*2* or *CYP2C19*3* (Kobayashi *et al*). Although all of known SNPs of *CYP2C19* gene (see <http://www.imm.ki.se/CYPalleles/>) have been analyzed, none of these mutated alleles were existed in the genomic DNA of this outlier, except for *CYP2C19*2*. Therefore, we sequenced all nine exons and exon-intron junctions of *CYP2C19* gene from the outlier and identified a novel SNP located in exon 9 of *CYP2C19* gene and the SNP was also analyzed in 80 Japanese reported herein.

Materials and Methods

Human DNA samples: Genomic DNA was isolated from whole blood of healthy volunteers using GFX genomic Blood DNA Purification kit (Amersham Biosciences, Piscataway, NJ, USA) in accordance with the manufacture's instructions. Informed consent was obtained, and the study including phenotyping and

Until January 27, 2004, the SNP reported herein has not been reported in the "Human cytochrome P450 (CYP) Allele Nomenclature Committee database (<http://www.imm.ki.se/CYPalleles/>) or the "JSNPs data base (<http://snp.ims.u.tokyo.ac.jp/>)".

*Kobayashi, K., Morita, J., Chiba, K., Wanibuchi, A., Kimura, M., Irie, S., Urae, A. and Ishizaki, T.: Pharmacogenetics in press.


Received; February 27, 2004, Accepted; May 3, 2004

To whom correspondence should be addressed: Kaoru KOBAYASHI, Ph.D., Laboratory of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan. Tel. & Fax. +81-43-226-2894, E-mail: kaoruk@p.chiba-u.ac.jp


Table 1. Primers used for the specific amplification and direct sequencing analysis of *CYP2C19* gene

amplified region	forward primer (5' to 3')	reverse primer (5' to 3')
Exon1	AGTGGCCTAGGTGATTGGCCACTT	TCAAAGTATTTTACTTTACAATGATCTC
Exons 2 and 3	TAAATATGAATCTAAGTCAGGCTTAGT	GGAGAGCAGTCCAGAAAGGTCAGTGATA
Exon 4	TGCTTTTAAGGGGAGTCATAGG	CAAATGTACTTCAGGGCTTGG
Exon 5	CAACCAGAGCTTGGCATATTG	TGATGCTTACTGGATATTCATGC
Intron 5	AAACCTTGCTTTTATGGAAAAGTG	ATAACTAAGCTTTTGTAAACATGTT
Exon 6	AAAACCTGGCACAAGACAGGGATG	AAATTGGGACAGATTACAGCTGCG
Exon 7	AATTGCTAGAACAAATGTTCCATTTT	AGAGGGTAAGAATCATACTGTGA
Exon 8	CCACTGTTTCATAAACCATCGTGA	GAAGGCACATGTAAGTTCCAACCTGA
Exon 9	ATCTACTCATCCCTCCTATGATTCACCG	ATGTGGCACTCAATGTAECTATTATAGA

A) Wild type/wild type



B) Wild type/168946C>T



C) Partial amino acid sequence of CYP2C19




Fig. 1. The nucleotide sequences of the *CYP2C19* gene in exon 9 containing 168946C>T polymorphism (Arg442Cys). Although the sequences are shown only for sense strands, both the strands were sequenced. The first A of the translational initiation codon ATG of exon 1 is defined as position + 1. A) Wild type/wild type. B) Wild type/168946C>T. C) Partial amino acid sequence of *CYP2C19* showing the conserved heme-binding motif (FXXGXRXCXG). Arrows indicate variant nucleotide and amino acid positions. Underlines indicate the conserved heme-binding motif of cytochrome P450.

genotyping tests was approved by the ethics review board of Kyushu Pharmacology Research Clinic and by the ethics committee of Graduate School of Pharmaceutical Sciences, Chiba University, Chiba Japan.

PCR conditions and DNA sequencing: The PCR was conducted in a reaction mixture (25 μ L) containing 100 ng of genomic DNA, 0.63 U Ampli Taq Gold (Applied Biosystems, Foster City, CA, USA), 10 \times PCR Gold Buffer, 2.5 mM MgCl₂ and 0.2 mM dNTPs with 0.2 μ M of each primer. PCR conditions consisted of an initial denaturation at 94°C for 10 min, followed by 35 cycles of denaturation at 94°C for 1 min, annealing at for 57°C 1 min and extension at 72°C for 1 min, except that annealing was performed at 65°C for amplification of exon 1. Sequences were determined using Cycle Sequencing with Quick Start Kit (Beckman coulter Fullerton, California, USA) and CEQ2000XL DNA analysis system (Beckman coulter). The primers used for the PCR amplification and sequencing are shown in Table 1. The SNP was confirmed by the repeated sequence analyses on PCR products generated by new genomic DNA amplification.

Mephobarbital phenotyping protocol: Thirty male healthy volunteers received an oral 200-mg dose of racemic mephobarbital (1 tablet of Prominal®, Winthrop Laboratories, Sydney, Australia). Urine samples were collected at 0 to 24 hours. The concentration of 4'-hydroxymephobarbital in urine was measured by the HPLC method. (Kobayashi *et al*¹). The genotypic backgrounds of CYP2C19 of thirty male healthy subjects were the nine homo extensive metabolizers (2C19*1/2C19*1), ten hetero extensive metabolizers (2C19*1/2C19*2, 2C19*1/2C19*3) and eleven poor metabolizers (2C19*2/2C19*2, 2C19*2/2C19*3, 2C19*3/2C19*3).

Results and Discussion

We found the following novel SNP (168946 C>T) from the outlier subject with a lowered capacity for CYP2C19-mediated 4'-hydroxylation of mephobarbital.

SNP: 040110MoritaJ001; GENENAME: CYP2C19; ACCESSION NUMBER: NT_030059.8; LENGTH: 25 bases; 5'-GAGGGCCTGGCCC/TGCATGGAGCT-GT-3'.

The SNP was 168946C>T in exon 9 resulting in an amino acid change of Arg442Cys (Fig. 1). The outlier was heterozygous for the Arg442Cys allele. As shown in Fig. 1C, the amino acid substitution (Arg442Cys) is closely located in the heme-binding region.² Thus, the novel SNP is expected to decrease the catalytic properties of CYP2C19. In fact, urinary excretion rate of 4'-hydroxymephobarbital collected in 0 to 24 hours after an oral administration of mephobarbital in the subject was lower than those in the other heterozygotes with

defective alleles, CYP2C19*2 or CYP2C19*3, or the homozygotes of CYP2C19*1 (3.5% vs. 10.1 \pm 1.1 or 10.9 \pm 1.5% of dose). However, the rate in the subject was not as low as those in poor metabolizers of CYP2C19 (0.53 \pm 0.31% of dose).

Until now, it has been known that the only two defective alleles (i.e., CYP2C19*2 and CYP2C19*3) account for >99% of poor metabolizer alleles in the Japanese population.^{3,4} On the other hand, more than 10 variants (designed as CYP2C19*4 to CYP2C19*15) of CYP2C19 gene have been reported from the other ethnic groups (see <http://www.imm.ki.se/CYPalleles/>). The novel SNP would be able to explain the poor metabolizer status of CYP2C19 which cannot be explained by CYP2C19*2 and CYP2C19*3 in a Japanese population. However, since this novel SNP was not found in another 80 DNA samples of Japanese subjects, further studies are definitely required for the more exact frequency of the SNP and its functional characteristics in Japanese and the other races.

In conclusion, the novel SNP (Arg442Cys) located in exon 9 of the CYP2C19 gene was found in a Japanese subject with an impaired activity of CYP2C19. This outlier appears to be a heterozygote for CYP2C19*2 and this new SNP, although haplotypes of the subject have not been evaluated. Further studies are undergone to establish whether the newly identified SNP (Arg442Cys) affects the CYP2C19 function in our laboratory.

Acknowledgement: This work was supported in part by grants-in-aid from the Ministry of Health, Labour and Welfare of Japan (Health and Labour Sciences Research Grants, Research on Human Genome, Tissue Engineering; Health and Labour Sciences Research Grants, Risk Analysis Research on Food and Pharmaceuticals), Tokyo, Japan (to K.C.).

References

- 1) Kobayashi, K., Kogo, M., Tani, M., Shimada, N., Ishizaki, T., Numazawa, S., Yoshida, T., Yamamoto, T., Kuroiwa, Y. and Chiba K.: Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes. *Drug Metab. Dispos.*, 29: 361-366 (2001).
- 2) Lewis, D. F. V.: The CYP2 family: models, mutants and interactions. *Xenobiotica*, 7: 617-661 (1998).
- 3) de Morais, S. M. F., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K. and Goldstein, J. A.: Identification of a new defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. *Mol. Pharmacol.*, 46: 594-598 (1994).
- 4) Kubota, T., Chiba, K. and Ishizaki T.: Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. *Clin. Pharmacol. Ther.*, 60: 661-666 (1996).